Optimi Health Corp. (CSE:OPTI)
5.70
-0.09 (-1.55%)
Oct 9, 2026, 3:59 PM EST
Optimi Health Revenue
Optimi Health had revenue of 140.20K CAD in the quarter ending June 30, 2026, a decrease of -28.61%. This brings the company's revenue in the last twelve months to 175.67K, down -67.95% year-over-year. In the fiscal year ending September 30, 2025, Optimi Health had annual revenue of 426.30K with 9.35% growth. That makes Optimi Health the 45,841st largest company in the world by revenue and 1,041st in Canada.
Revenue (ttm)
175.67K
Revenue Growth
-67.95%
P/S Ratio
185.79
Revenue / Employee
n/a
Employees
n/a
Market Cap
32.64M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 426.30K | 36.45K | 9.35% |
| Sep 30, 2024 | 389.85K | 208.76K | 115.28% |
| Sep 30, 2023 | 181.09K | 100.37K | 124.35% |
| Sep 30, 2022 | 80.72K | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| iAnthus Capital Holdings | 197.59M |
| Planet 13 Holdings | 131.28M |
| 1CM Inc. | 75.45M |
| Rubicon Organics | 64.23M |
| LSL Pharma Group | 41.83M |
| MediPharm Labs | 41.46M |
| Medicure | 32.08M |
| ZYUS Life Sciences | 374.00K |
Optimi Health News
- 2 days ago - Optimi Health to Present at the ThinkEquity Conference - Financial Post
- 2 days ago - Optimi Health to Present at the ThinkEquity Conference - GlobeNewsWire
- 10 days ago - Optimi Health Appoints Melanie Pump to Board of Directors - GlobeNewsWire
- 16 days ago - Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply - GlobeNewsWire
- 17 days ago - Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer - Financial Post
- 17 days ago - Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer - GlobeNewsWire
- 23 days ago - Optimi Health Plans Phase 3 Trial Of MDMA-Assisted Therapy For PTSD - Nasdaq
- 23 days ago - Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder - Financial Post